Mirae Asset Global Investments Co., Ltd. I Mab Transaction History

Mirae Asset Global Investments Co., Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$8.27 - $18.43 $483,513 - $1.08 Million	-58,466 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$12.54 - $46.93 $31,149 - $116,574	-2,484 Reduced 4.08%	58,466 $949,000
Q4 2021 Feb 08, 2022	BUY	$45.28 - $74.5 $1.22 Million - $2.01 Million	26,920 Added 79.11%	60,950 $2.89 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $1.74 Million - $2.58 Million	30,500 Added 864.02%	34,030 $2.47 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $168,945 - $296,343	3,530 New	3,530 $297,000

13.8M

20K

13.3K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $155M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.